

Prof. Harald Mischak, PhD MD

Position :Director

Department :

Affiliation :Mosaiques Diagnostics

Office : Rotenburger Str. 20 D-30659 Hannover GERMANY

E-mail : mischak@mosaiques-diagnostics.com

Homepage : www.mosaiques-diagnostics.com

Education

yyyy.mm-yyyy.mm	degree	affiliation
1979 - 1984:	Dipl Ing	TU Vienna
1984-1986	PhD	TU Vienna
199-1995	MD	TU Munich

Professional Experience

1986 - 1993:	Hochschul-Assistent at the Institute for Biochemistry, University of Vienna
Sep.-Dec.1988:	Invited scientist (funded by the Fulbright Foundation) to the Laboratory of Viral Carcinogenesis,NIH,NCI, FCRF, Frederick, Maryland, USA
1989 - 1990:	Schroedinger Fellow at the Lab. of Genetics, NIH, NCI, Bethesda, Maryland, USA
1990 - 1993:	Fogarty Fellow at the Lab. of Genetics, NIH,NCI.
1993 -1997:	Scientific Group Leader at the Inst.f. Klin. Mol. Biol., GSF, Munich, Germany
1998 - 1998:	Scientific Group Leader at the Technische Universität München, Institute for Immunologie
1998 - 1999:	Scientific Group Leader at Franz-Volhard Klinikum, MDC, Berlin ´Buch.
1998 - 1999:	Visiting Scientist, Laboratory of Molecular Biology, NIDDK, NIH, Bethesda (Maryland, USA).
1999 - 2006:	Professor, MH Hannover, GERMANY
2002 - date:	Director of Mosaiques Diagnostics GmbH
2010 – date:	Professor, University of Glasgow, UK

Academic Society

yyyy.mm-yyyy.mm	position	society
-----------------	----------	---------

Selected Publications

Mischak,H. et al (2010). Recommendations for biomarker identification and qualification in clinical proteomics. *Sci. Transl. Med.* 2, 46ps42.

Mischak,H et al. (2012). Implementation of proteomic biomarkers: making it work. *Eur. J Clin Invest* 42, 1027-1036.

Zurbig,P et al. (2012). Urinary proteomics for early diagnosis in diabetic nephropathy. *Diabetes* 61 , 3304-3313.

Mischak,H., Vlahou,A., and Ioannidis,J.P. (2013). Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. *Clin Biochem.* 46, 432-443.

Metzger,J., et al. (2013). Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders. *Gut* 62, 122-130.

Schanstra,J.P., et al. (2015). Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. *J Am Soc. Nephrol.* 26, 1999-2010.

Frantzi,M., et al. (2016). Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study. *Clin. Cancer Res.* 22, 4077-4086.

Pontillo,C. and Mischak,H. (2017). Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. *Clinical Kidney Journal* 10, 192-201.